Chione
VC Fund
Berlin, Germany
Chione is an investment company that aims to finance companies in the biomedical sector.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Chione invests in
Health CareBiotechnologySensorMedicalHospital
Stages Chione invests in
Series BSeries DSeedSeries ASeries C
Countries Chione invests in
United StatesIsraelFinlandGermany
Round sizes
Series B $5M–$100MSeries D $36M–$136M
Round size
- Series B
- $5M–$100M
- Series D
- $36M–$136M
Investment Focus
Industry
- Health Care 2 (22%)
- Biotechnology 2 (22%)
- Sensor 1 (11%)
- Medical 1 (11%)
- Hospital 1 (11%)
Stage
- Series B 2 (22%)
- Series D 2 (22%)
- Seed 1 (11%)
- Series A 1 (11%)
- Series C 1 (11%)
Country
- United States 2 (22%)
- Israel 1 (11%)
- Finland 1 (11%)
- Germany 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Prisma photonics helps to keep the most critical large-scale infrastructure running. Introducing the next generation of utility monitoring paving the way to smarter, safe, and efficient operations. We empower our customers and provide them with the best actionable insights on their assets, enabling them to move to a new era of digitalization.Prisma Photonics was founded in 2017 by a strong team of entrepreneurs, highly experienced in lasers, optical fiber, algorithms, and machine learning. Combining talent from the physics and laser world with algorithmic and machine learning expertise. The company is now in commercial deployment stage. | $30M / Oct 15, 2025 | ||
| Prisma photonics helps to keep the most critical large-scale infrastructure running. Introducing the next generation of utility monitoring paving the way to smarter, safe, and efficient operations. We empower our customers and provide them with the best actionable insights on their assets, enabling them to move to a new era of digitalization.Prisma Photonics was founded in 2017 by a strong team of entrepreneurs, highly experienced in lasers, optical fiber, algorithms, and machine learning. Combining talent from the physics and laser world with algorithmic and machine learning expertise. The company is now in commercial deployment stage. | $20M / Series C / Sep 12, 2023 | ||
| ICEYE is a space technology company that develops and operates a constellation of synthetic aperture radar (SAR) satellites used for Earth observation and persistent monitoring. The company provides satellite imagery and data that enable governments, defense organizations, insurers, financial institutions, and other commercial users to monitoractivities and environmental conditions across the globe. Its SAR technology captures imagery regardless of cloud cover, weather conditions, or time of day, supporting applications such as disaster response, infrastructure monitoring, maritime awareness, environmental monitoring, and security operations. ICEYE also delivers satellite-based intelligence systems and analytical solutions that help organizations assess events, track changes, and make operational decisions using near real-time information. Through its satellite network and data services, the company supports monitoring and situational awareness across a range of public and commercial sectors. | $136M / Series D / Feb 03, 2022 | ||
| Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethalcontexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. | $100M / Series B / Nov 11, 2021 | ||
| Prisma photonics helps to keep the most critical large-scale infrastructure running. Introducing the next generation of utility monitoring paving the way to smarter, safe, and efficient operations. We empower our customers and provide them with the best actionable insights on their assets, enabling them to move to a new era of digitalization.Prisma Photonics was founded in 2017 by a strong team of entrepreneurs, highly experienced in lasers, optical fiber, algorithms, and machine learning. Combining talent from the physics and laser world with algorithmic and machine learning expertise. The company is now in commercial deployment stage. | $10M / Series A / Jan 01, 2020 | ||
| Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $36M / Series D / Nov 13, 2019 | ||
| Digital advertising as a service | Seed / May 20, 2016 | ||
| Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $20M / Series B / Jan 07, 2015 | ||
| Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $5M / Series B / Nov 18, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
48,825 investors
Hardware Investors
46,344 investors
Biotech Investors
24,243 investors
Biotechnology Investors
21,493 investors
Medical Investors
21,329 investors
Health Care VC Funds
36,610 investors
Hardware VC Funds
35,702 investors
Biotech VC Funds
20,947 investors
Biotechnology VC Funds
18,846 investors
FAQ
What does Chione invest in?
Chione invests primarily in Health Care, Biotechnology and Sensor startups, most often at Series B and Series D stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Chione invest in?
Chione typically joins rounds of $5M–$100M at Series B and $36M–$136M at Series D. These are whole funding-round sizes, not Chione's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Chione took part in.
When did Chione last invest?
The most recent investment recorded for Chione closed in Oct 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
